.Nature Medicine, Released online: 09 Oct 2024 doi:10.1038/ s41591-024-03316-9Delandistrogene moxeparvovec received FDA confirmation after an unfavorable test, which highlights the numerous complications as well as obstacles of drug growth in this particular setting.